Showing 1951-1960 of 5627 results for "".
- Vision Expo 2026 Marks 40 Years With Expanded Education Experiencehttps://modernod.com/news/vision-expo-2026-marks-40-years-with-expanded-education-experience/2485286/Produced by RX and The Vision Council, Vision Expo is celebrating its 40th year in 2026 with an enhanced educational conference designed to deliver greater access, flexibility and real-world learning for vision care professionals.
- Y.ora Vision and Eyexora Global Partner with SERI to Advance New MIGS Platform for Glaucomahttps://modernod.com/news/yora-vision-and-eyexora-global-partner-with-seri-to-advance-new-migs-platform-for-glaucoma/2484184/Y.ora Vision, a newly formed ophthalmic medical device company, announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a next-generation minimally invasive surgical device for the treatment o
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin
- Sanofi’s Intravitreal Gene Therapy Earns FDA Fast Track Designation for Geographic Atrophyhttps://modernod.com/news/sanofis-intravitreal-gene-therapy-earns-fda-fast-track-designation-for-geographic-atrophy/2482888/The FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the developm
- iStar Medical Announces Positive 5-year Results of MINIject® in Glaucoma Patientshttps://modernod.com/news/istar-medical-announces-positive-5-year-results-of-miniject-in-glaucoma-patients/2482760/iStar Medical has announced positive 5-year results from the STAR-GLOBAL trial for their MINIject®device in patients with open-angle glaucoma. STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of MINIject® up to five years after im
- Surgilūm's RoboMarker G2 Receives 5 International Medical Device Design Awardshttps://modernod.com/news/surgilums-robomarker-g2-receives-5-international-medical-device-design-awards/2482638/Surgilūm's RoboMarker G2 was awarded international medical device design awards by 3 associations. The awards include: New York Product Design Award: an international competition celebrating excellence in product desi
- Pantheon Vision Advances Corneal Implant Developmenthttps://modernod.com/news/pantheon-vision-advances-corneal-implant-development/2482627/Pantheon Vision announced the completion of its third meeting with the FDA review team as the company continues its development of bioengineered corneal implants, designed to address the global challenge of corneal blindness. Over the past year, Pan
- Visible Genomics Wins 2025 AMD Genetic Testing Company of the Year Awardhttps://modernod.com/news/visible-genomics-wins-2025-amd-genetic-testing-company-of-the-year-award/2482619/Visible Genomics, a provider of genetic testing solutions for severe ocular diseases, was named 'Life Sciences Review AMD Genetic Testing Company of the Year 2025.' This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degene
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- Hoya Highlights the Impact Rural vs Urban Living Environments May Have On Myopia In Young Childrenhttps://modernod.com/news/hoya-highlights-the-impact-rural-vs-urban-living-environments-may-have-on-myopia-in-young-children/2482457/Hoya Vision Care announced the results of a 5-year epidemiological study conducted in Scotland exploring the correlations between myopia, socio-economic deprivation, and urban or rural dwellings in young children. The study, which reviewed refractive error data from eye examinations in